WO2007062546A1 - Iron-saccharide complexs easy to reconstitute and the method for manufacture them - Google Patents

Iron-saccharide complexs easy to reconstitute and the method for manufacture them Download PDF

Info

Publication number
WO2007062546A1
WO2007062546A1 PCT/CN2005/002056 CN2005002056W WO2007062546A1 WO 2007062546 A1 WO2007062546 A1 WO 2007062546A1 CN 2005002056 W CN2005002056 W CN 2005002056W WO 2007062546 A1 WO2007062546 A1 WO 2007062546A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron
sodium
reaction
solution
amount
Prior art date
Application number
PCT/CN2005/002056
Other languages
French (fr)
Chinese (zh)
Inventor
Jinmai Xiao
Jie Deng
Bo Xiao
Jin Feng
Original Assignee
Chongqing Pharmaceutical Research Institute Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Pharmaceutical Research Institute Co., Ltd. filed Critical Chongqing Pharmaceutical Research Institute Co., Ltd.
Priority to PCT/CN2005/002056 priority Critical patent/WO2007062546A1/en
Publication of WO2007062546A1 publication Critical patent/WO2007062546A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Definitions

  • Iron-sugar composition capable of reconstitution and preparation method thereof
  • the present invention relates to a powdered pharmaceutical composition, in particular to a powder composition comprising a therapeutically effective amount of an active pharmaceutical ingredient iron hydroxide-sugar complex and at least one additive, and to prepare a novel injectable iron having therapeutic activity - A method of carbohydrate complex.
  • the complex can be injected to treat iron deficiency.
  • the complex can be conveniently reconstituted in water prior to administration. Background technique
  • Iron-saccharide complexes and their derivatives are one of several FDA-approved blood-suppressive drugs for the treatment of iron deficiency.
  • Iron deficiency is a blood disorder that can be caused by congenital genetic defects or other medical abnormalities. It is known that kidney disease, repeated renal dialysis, and certain cancer therapies can cause iron deficiency. "Blood medicine,” means an agent that stimulates the formation of blood cells and/or increases the level of hemoglobin in the blood.
  • the treatment of iron deficiency can be divided into two categories: oral supplementation and injection supplementation.
  • the oral supplemental administration method is to improve the symptoms of iron deficiency by oral administration of a simple iron salt such as ferrous sulfate and ferrous gluconate. If oral supplementation does not achieve the desired results, consider the use of supplemental administration as the next stage of treatment, with intravenous and intramuscular injections being two common methods of administration.
  • iron dextran which is a complex of iron hydroxide and dextran. Once injected into the body, iron dextran is rapidly absorbed by the cells and decomposed into iron and dextran, and then enters different metabolic pathways.
  • the second type of supplement is particularly useful as a safer drug for the treatment of iron deficiency.
  • the iron-saccharide complex does not contain polymonosaccharides.
  • the two types of iron-saccharide complexes currently available on the market have a skeleton structure formed by gluconate and/or sucrose in combination with ferric ions.
  • the first type of iron-saccharide complex is sodium iron gluconate-sucrose complex (SFGCS).
  • SFGCS is a macromolecular complex with an apparent molecular weight greater than 350,000 Daltons.
  • iron-saccharide complex In comparison, another type of iron-saccharide complex is much smaller, with an apparent molecular weight of less than 80,000 Daltons.
  • iron-saccharide complexes are chemically referred to as iron hydroxide-sugar complexes (FHSC).
  • the prior art methods for preparing iron-saccharide complexes either lack a final drying step or require an additional purification step to adequately remove the excipients prior to drying. This additional purification step not only reduces the overall yield but also increases the total cost of production. Therefore, it is necessary to improve the process so that the iron-saccharide complex is dried into a powder after completion of the reaction without removing the excipient.
  • the method of the present invention solves the above problems and provides a method of preparing an iron-saccharide composite dry powder.
  • An advantage of the present invention is that it makes the necessary salts or other excipients, here mainly referred to as inorganic chlorides, especially NaCl which can be added to the iron-saccharide complex prior to drying.
  • the iron-saccharide complex can be dried after the reaction is completed without prior removal of salts or other excipients. According to this scheme, the concentration of salt or other excipients will be maintained after drying.
  • the method is applicable to both iron-saccharide complexes of SFGCS and FHSC, as well as derivatives and mixtures thereof. Since the iron-saccharide complex is unstable in solution, it is advantageous to store and transport these compounds in the form of a dry powder. Although there have been various methods for preparing these two iron-saccharide complexes, few methods for preparing dry powders of such compounds have been disclosed.
  • a defined, repeatable amount of the necessary salt or other excipient can be added to the final dried product.
  • these inactive ingredients can be added after the pure active pharmaceutical ingredient has dried.
  • the introduction of these inactive ingredients prior to drying allows these ingredients to be more homogeneously mixed with the active pharmaceutical ingredients. Evenly.
  • It is advantageous to add the necessary excipients prior to drying because the excipients do not have sterility requirements. This improvement is significant because it allows the drug manufacturer to make the blood-blend into an easily miscible powder, and the generic drug manufacturer can conveniently reconstitute the drug powder in water prior to sale. After the bulk drug is made, only purified water needs to be added. Thus, the method reduces the likelihood of errors by removing additional purification steps.
  • the amount of salt or excipient that is added is determined by determining the salt content of the reaction mixture.
  • the salt and other excipients are dried together with the active ingredient, i.e., the iron-saccharide complex.
  • the salt referred to herein mainly refers to an inorganic chloride, preferably NaCL, which is a new and improved method for the drug manufacturer to make the blood-mixing drug into an easily-mixable powder.
  • the generic drug manufacturer can deliver it for clinical use before delivery.
  • the powder is conveniently reconstituted in water.
  • an active pharmaceutical ingredient iron hydroxide-saccharide complex
  • at least one additive and optionally an excipient wherein the additive
  • the inorganic chloride such as potassium chloride, sodium chloride or the like
  • sodium chloride is preferred.
  • the iron hydroxide-sugar complex is preferably an iron hydroxide-sucrose complex or a sodium iron gluconate-sucrose complex.
  • the formula of the iron hydroxide-sucrose complex is [Na 2 Fe 5 0 8 (OH).3(H 2 0)] n m(C 12 H 22 Ou), wherein n is any integer from 1 to 30 m is any integer from 1-360. Preferably n is any integer from 5 to 20, and m is any integer from 60 to 240.
  • the effective therapeutic amount of the iron hydroxide-sugar complex herein means that the iron content is 1-20% by weight, preferably 5-10% by weight, of the iron hydroxide-sugar complex.
  • the dosage range is from 500 mg to 4 g, preferably from 1 to 3 g, more preferably from 1.5 to 2 g.
  • an additive such as sodium chloride is added to the reaction mixture before the synthesis of the iron hydroxide-sugar complex or during the synthesis of the iron hydroxide-saccharide complex, and after the reaction is completed, no separation is required.
  • Impurities, the reaction mixture containing the reaction product iron hydroxide-sugar complex may be directly subjected to freeze drying or spray drying, preferably spray drying.
  • the amount of the additive such as sodium chloride in the pharmaceutical composition of the present invention is calculated according to the following Equation I.
  • Equation I 1.06%- C reverse) /35.5
  • the amounts are all by weight.
  • Another object of the present invention is to provide an iron hydroxide suitable for injection by a human or an animal.
  • At least one sugar or sugar derivative or a mixture thereof is contacted with Fe(III) ions and inorganic chloride in the presence of OH- ions.
  • the term "contacting" as used herein refers to mixing together for chemical reaction or chemical reaction.
  • the reactants of the process react in an aqueous medium.
  • the Fe(m) ion referred to in the method of the present invention is preferably present in the form of iron hydroxide, and the iron hydroxide can be prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions.
  • the aqueous alkaline solution referred to in the process of the present invention is selected from the group consisting of sodium hydroxide, sodium carbonate and aqueous sodium hydrogencarbonate, preferably sodium carbonate or sodium hydrogencarbonate.
  • the method of the present invention may further comprise, according to actual needs, drying unreacted sodium chloride together with a reaction product, such as an iron hydroxide-sucrose complex, to form a final product, i.e., a powder composition.
  • a reaction product such as an iron hydroxide-sucrose complex
  • the amount of sodium chloride used in the process of the present invention is calculated according to Equation I above.
  • a further object of the present invention is to provide a process for the preparation of an iron-saccharide complex suitable for parenteral administration to humans or animals, which method comprises the following steps:
  • the reaction of the method is carried out in an aqueous medium, wherein the Fe(m) ion is preferably present in the form of iron hydroxide, and the iron hydroxide is prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions, wherein The aqueous alkaline solution is selected from the group consisting of sodium hydroxide, sodium carbonate and aqueous sodium hydrogencarbonate, preferably sodium carbonate or hydrogencarbonate.
  • the final reaction mixture of the process is dried by a freeze or spray drying process, preferably a spray drying process.
  • the air temperature during spray drying is about 70 ° C to 100 ° C, where the air feed rate is between 30 Hz and 50 Hz.
  • the pre-cleaning of air before entering the spray drying chamber should reach 100,000 level.
  • the speed is between approximately 1 Hz and 3 Hz.
  • the sodium chloride added in the process is dried with a reaction product such as an iron hydroxide-sucrose complex to form a dry powder product which can be rapidly reconstituted in a suitable solvent prior to administration.
  • the amount of sodium chloride used in the process is calculated according to Equation I above.
  • iron-saccharide complex In the method for preparing an active blood-enriching ingredient (iron-saccharide complex) which is powdered and mixed with a suitable excipient, the "iron” ion refers not only to iron ions in a solution, but also to other complexes such as a hydroxyl group. Forms of iron ions. Similarly, OPT includes OH_ in the iron hydroxide precipitate.
  • “Complex” refers to a complex or polymer of molecules, iron and certain sugars.
  • "Auxiliary material” means any molecule, component, compound or complex that has no blood-filling activity.
  • excipients in a broad sense include unreacted starting materials, by-products, degradation products, buffers, diluents, preservatives, salts, and the like. Excipients can also be added to the reaction mixture to adjust the chemical and/or physical properties of the final product. Such excipients may also be referred to as “additives” or “excipients”.
  • the iron-saccharide complex of the present invention may be composed of a skeleton structure formed of a sugar or a derivative thereof and iron.
  • the process of the invention can be used to prepare powdered iron-sugar complexes.
  • a useful reagent should contain at least one sugar and a substance that provides a source of ferric ions.
  • sugar refers to monosaccharides and oligosaccharides.
  • “Monosaccharide” refers to a single sugar unit without a glycosidic bond. These include aldoses, disaccharides, aldoses, ketoses and diketoses, as well as deoxysaccharides and amino sugars, as well as derivatives thereof. Examples of monosaccharides include dihydroxyacetone, glyceraldehyde, Red sugar, ribose, sorbose, pentose, arabinose, levulose, galactose and manose. “Oligosaccharide” refers to a sugar in which ten or more monosaccharides are combined.
  • Oligosaccharides include, but are not limited to, sucrose, maltose, cellobiose, isomaltose, gentiobiose, melibiose, rutose, primrose, trehalose, lactose, and derivatives thereof. Preferred is sucrose.
  • “Sugar derivative” means a compound derived from the monosaccharide or oligosaccharide.
  • a sugar comprising one or more terminal groups which are oxidized to a carboxyl group, a thiol group is reduced, and one or more hydroxyl groups are replaced by a hydrogen, an amino group, a sulfhydryl group or the like.
  • oxidized sugars include gluconate salts obtained by oxidation of glucose. These oxidized sugar groups can be ionized based on their ionization constant and pKa value. The ionized sugar is called a sucrose salt or a sugar acid, and its protons remain on the ionized sugar.
  • a sugar salt is formed.
  • suitable sugar or sugar derivatives include those which are similar in nature to the sugars described above.
  • a preferred sugar derivative is a gluconate such as sodium gluconate.
  • sugars and derivatives thereof useful in the present invention must be sufficiently soluble in water.
  • Naturally occurring or synthetic sugars and derivatives thereof, including the sugars of the D and L optical isomers or their racemic mixtures, are suitable for use in the present invention.
  • Derivatives of sugars may include sugar based acids, salts, methyl esters, amines and alcohol derivatives.
  • Acids include, but are not limited to, gluconic acid, dextrose diacid, hydroxy acid fructose, alpha-mercapto tyrosine, uronic acid, sucrose diacid, mannoic acid, saccharide acid, galacturonic acid, glucuronic acid, mannose Uronic acid, xylic acid, tartaric acid, galactonic acid, glyceric acid, lactic acid, arabinose dihydroxy acid, mannose dihydroxy acid, glucose dihydroxy acid, maltoic acid, and lactanoic acid.
  • the salt may be composed of uronic acid and an alkali metal or alkaline earth metal including, but not limited to, lithium, sodium, potassium, rubidium, magnesium, calcium, strontium and barium.
  • a particularly useful salt therein is sodium gluconate.
  • Amines include, but are not limited to, fucosylamine (2-amino-2,6-dideoxygalactose), galactosamine (2-amino-2-deoxygalactose), acosamine (3-amino-2,3, 6-tripaoxy-L-wood-hexose), bacitracin (2,4-diamino-2,4,6-trideoxy-0-glucose), glucosamine (2-amino-2-deoxyglucose), etc. .
  • Alcohols include, but are not limited to, mannitol, glucose alcohol, arabitol, xylitol, fucitol, rhamitol, erythritol, ribitol, galactitol, glycerol, and the like.
  • polymeric sugars or polysaccharides such as starch, cellulose, dextran and dextrin are not suitable for use in the present invention.
  • the iron-saccharide complex of the present invention does not contain a significant amount of polysaccharide.
  • significant quantity is defined as the concentration of polysaccharide that causes an adverse reaction, such as an allergic reaction caused by an iron-saccharide complex when administered to a patient parenterally.
  • the iron-saccharide complex referred to in the present invention is preferably an iron-sucrose complex or a sodium iron gluconate complex.
  • the reaction for preparing the iron-saccharide complex is preferably carried out in an aqueous phase or an environment which is actually an aqueous phase.
  • substantially aqueous phase means that a portion of the reaction medium can include a non-aqueous liquid, and the reaction to form an iron-saccharide complex within this extent is not significantly affected. More suitably, the reaction medium is almost entirely water.
  • the iron ion is preferably a ferric ion, not a divalent iron ion.
  • a soluble or dispersible trivalent iron-containing compound can be used as a source material of Fe(m). These materials include, but are not limited to, iron chloride, ferric nitrate, ferric sulfate, iron carbonate, ferric citrate, and iron hydroxide. Iron hydroxide is particularly useful in the present invention, but the other iron salts described above can be used to prepare iron hydroxide. Although most of the iron salts are available, it is best to use iron salts which are slightly soluble in water.
  • the iron hydroxide is preferably in a solid precipitated state or in a dispersed colloidal state.
  • the colloid is composed of a substance divided into fine particles (gel particles) dispersed in another substance.
  • a colloid is considered to be a physical state between a solution and a suspension.
  • the size of the ferric hydroxide colloid is in the range of 1 nm to 100 nm.
  • Truste solution means a homogeneous mixture of two or more substances. In “true solution”, the particle size of the solute approximates the size of the molecule, which is much smaller than the particle size of the colloid or suspension.
  • solution refers to a wide range, including true solutions and colloids, and mixtures thereof. Therefore, the reaction mixture solution may refer to an iron hydroxide colloid mixed with an unreacted substance dissolved in a "true solution”.
  • an aqueous solution of an iron salt can be used to prepare iron hydroxide. Or, buy iron hydroxide directly from the market.
  • bases or salts which hydrolyze to produce (OH)-ions can be used to prepare iron hydroxide intermediates.
  • bases or salts include sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogencarbonate.
  • Ferric chloride hexahydrate is the best source of Fe(III) ions.
  • Sodium carbonate is the best raw material for the preparation of iron hydroxide by reaction with iron salts.
  • iron hydroxide is prepared by reacting an iron salt with a base or a basic compound such as sodium carbonate
  • the iron salt and the base or basic compound may be mixed in the form of a solid or a solution. It is best to completely dissolve the iron salt first. In water, the sodium carbonate solution was slowly added dropwise to the iron salt solution. Stirring for 10-30 minutes gives the iron hydroxide intermediate.
  • the iron hydroxide can be used directly in the subsequent reaction with sugar. The sugar is added as a solid or a solution to the iron hydroxide which has been dispersed or colloidal.
  • the reaction is preferably terminated by centrifugation and washed with water to collect the filter cake.
  • the iron hydroxide is preferably washed with water to facilitate determination of its weight.
  • the water content of the wet iron hydroxide was measured to determine the net weight of the iron hydroxide.
  • the sugar in the form of a solid or solution is mixed with iron hydroxide in the presence of water.
  • a certain amount of sodium hydroxide solution was added dropwise to adjust the pH of the reaction solution.
  • the reaction was stirred and heated slowly to promote dissolution. The amount of sugar, water and sodium hydroxide charged is calculated based on the amount of iron hydroxide added.
  • the feed ratio (w/w) is:
  • a is any number in the range 5-12, a is preferably between 8-9; b is any number between 0.1-0.3, b is preferably between 0.15-0.25; c is 10- Any number between 15 and c is preferable between 12-13.
  • Weight of iron hydroxide (dry) weight of iron hydroxide intermediate X iron content of iron hydroxide intermediate X 106.86/55.84
  • the iron hydroxide intermediate means a wet product of iron hydroxide (aqueous iron hydroxide).
  • the feed ratio (w/w) in one example of the present invention is:
  • the total water comprises water of the iron hydroxide intermediate, which corresponds to the total weight of the intermediate minus the net weight of the iron hydroxide.
  • the total water also includes sodium hydroxide solution and water from other solutions.
  • the solution should be sampled for chlorine and iron content to determine the weight of sodium chloride to be added.
  • the weight of sodium chloride is calculated by the following equation:
  • the amounts are all by weight.
  • the amount of sodium chloride added is obtained according to the above calculation formula.
  • the total reaction mixture was filtered while the filtrate was distilled at 100 ° C to 120 ° C.
  • the temperature of the distillation tank and the cloud point of the reaction mixture should be monitored. When the cloud point reaches a set value, which is any value between 4.6 and 5.1, the distillation is stopped. A small amount of water was added while the reaction mixture was still hot. The reaction mixture was agitated and then the specific gravity of the solution was measured. If the specific gravity is above 1.35 g/ml, add water until the specific gravity of the solution is between 1.25-1.35 g/ml. The prepared iron-sucrose solution was cooled and dried.
  • the final product can also be dried using other drying methods, and the final iron-sucrose solution is preferably dried by spray drying. Pre-cleaning of compressed air and hot air should reach the 100,000 level.
  • the material in the dryer should be fluidized. The fluidized liquid is first passed through a peristaltic pipetting pump and then atomized into a very fine droplet by compressed air and then injected into the dryer through a sprayer. Hot air is also used to promote drying.
  • the drying parameters are as follows: The material input speed is between l-3Hz.
  • the air temperature is approximately 70. C to 100. C.
  • the material temperature is approximately 50. C to 75. C.
  • the air input speed is 30-50Hz.
  • the dried material was cooled and weighed.
  • the dried iron-sucrose complex is comminuted through a 40 mesh screen.
  • the screened composite is preferably remixed to obtain a uniform iron-sucrose complex powder.
  • the dry powdered composite was loaded into a two-layer PE bag and then sealed. Put the sealed PE bag into the aluminum-plastic composite bag and seal it, then put it into the aluminum to listen, seal and label.
  • the dry iron-sucrose complex can be packaged in 10kg, 5kg, lkg, 500g, 250g, 50g or packaged according to customer needs.
  • the range of chemicals, compounds, and amounts supplied is provided as a general guide.
  • the sucrose in the saccharides used herein is for illustrative purposes only. It is possible for a person skilled in the art to find other similar chemicals or ranges that can be completed without departing from the spirit of the invention. detailed description
  • Anhydrous sodium carbonate 9.30 g was weighed and dissolved in 100 g of purified water. Another weighed 14.50g of ferric chloride hexahydrate, added to 60g of purified water, stirred and dissolved. After the ferric chloride is completely dissolved, the prepared sodium carbonate solution is added to the ferric chloride solution. After the sodium carbonate solution is added, stirring is continued for a while, centrifuged with a centrifuge, and washed with purified water. The precipitate is collected to obtain an iron hydroxide intermediate.
  • the reactants were placed in the flask in the following proportions:
  • Example 3 The iron-sucrose complex solution obtained in Example 1 was added, purified water was added to a specific gravity of 1.26 g/ml, placed in a stainless steel tray, placed in a lyophilizer, and vacuum-dried for 30 hours to obtain a water-soluble solution. A tan powder containing a predetermined amount of chloride ions.
  • Example 3 The iron-sucrose complex solution obtained in Example 1 was added, purified water was added to a specific gravity of 1.26 g/ml, placed in a stainless steel tray, placed in a lyophilizer, and vacuum-dried for 30 hours to obtain a water-soluble solution. A tan powder containing a predetermined amount of chloride ions.
  • Anhydrous sodium carbonate 139.5 g was weighed and dissolved in 1500 g of purified water. Further, 217.5 g of ferric chloride hexahydrate was added, and it was added to 900 g of purified water, and stirred to dissolve. After the ferric chloride was dissolved, the prepared sodium carbonate solution was added to the ferric chloride solution, and then stirred for 10 minutes, centrifuged with a centrifuge, and washed with purified water. The precipitate is collected to obtain the intermediate iron hydroxide.
  • sucrose, dissolved water and sodium hydroxide according to the above ratio; from the dissolved water, take the appropriate amount
  • the purified water dissolves the sodium hydroxide; the dissolved water, sucrose, and the intermediate are sequentially added to the solution tank; the stirring is turned on; then the sodium hydroxide solution is added to close the feed port.
  • Slow heating Temperature When the material is completely dissolved, sample and check the chlorine content and iron content, restart the stirring after sampling, and continue heating. According to the test result, the amount of additional sodium chloride is calculated according to the above equation I, and the calculated amount of sodium chloride is calculated and added to the reaction liquid.
  • the heating steam pressure is controlled, and the reaction temperature is controlled between 100 and 120 ° C; the reaction is carried out while distilling.
  • the cloud point reached 5.0
  • the reaction reached the end point.
  • the reaction is diluted with an appropriate amount of purified water, and the specific gravity of the solution is adjusted between 1.25 and 1.35 g/ml.
  • the iron-sucrose complex stock solution is dried by spray drying, and the compressed air and hot air used in the drying process are purified and up to the requirements of 100,000 cleanliness.
  • a trap bag is placed on the upper portion of the dryer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses a new pharmaceutical composition comprising, in well-distributed powder form : iron-saccharide complex and salt agent in a suitable amount or other excipient . It also discloses the process for preparation the composition , wherein the salt or other excipient is added before iron-saccharide complex is being dried . This improved process make API manufacturer prepare the hematinic powder which can be used just mixed with water , moreover , the powder is easy to reconstitute in water by the ordinary manufacturer .

Description

一种易复溶的铁 -糖类组合物及其制备方法 技术领域  Iron-sugar composition capable of reconstitution and preparation method thereof
本发明涉及一种粉末状药用组合物, 具体为包含有效治疗量的活性 药物成分氢氧化铁-糖复合物和至少一种添加剂的粉末组合物,以及制备 具有治疗活性的新型注射用铁 -糖类复合物的方法。该复合物可注射治疗 铁缺乏症。 该复合物可于给药前方便地复溶于水中。 背景技术  The present invention relates to a powdered pharmaceutical composition, in particular to a powder composition comprising a therapeutically effective amount of an active pharmaceutical ingredient iron hydroxide-sugar complex and at least one additive, and to prepare a novel injectable iron having therapeutic activity - A method of carbohydrate complex. The complex can be injected to treat iron deficiency. The complex can be conveniently reconstituted in water prior to administration. Background technique
铁 -糖类复合物及其衍生物是 FDA批准的用于治疗铁缺乏症的几类 补血药物之一。 铁缺乏症是一种血液疾病, 可由先天性的基因缺陷或者 其他内科异常引起。 已知肾病、 重复肾透析以及某些癌症疗法均可引起 铁缺乏症。 "补血药,, 指可刺激血细胞的形成和 /或提高血液中血红蛋白 水平的试剂。  Iron-saccharide complexes and their derivatives are one of several FDA-approved blood-suppressive drugs for the treatment of iron deficiency. Iron deficiency is a blood disorder that can be caused by congenital genetic defects or other medical abnormalities. It is known that kidney disease, repeated renal dialysis, and certain cancer therapies can cause iron deficiency. "Blood medicine," means an agent that stimulates the formation of blood cells and/or increases the level of hemoglobin in the blood.
根据给药途径的不同, 铁缺乏症的治疗可分为两类: 口服补充给药 法及注射补充给药法。 口服补充给药法即患者通过口服硫酸亚铁和葡萄 糖酸亚铁之类的简单铁盐, 以改善铁缺乏症状。 若口服补充给药法无法 达到预期的效果, 则考虑将注射补充给药法作为下一阶段的治疗, 其中 静脉注射及肌肉注射为两种常用给药方法。  Depending on the route of administration, the treatment of iron deficiency can be divided into two categories: oral supplementation and injection supplementation. The oral supplemental administration method is to improve the symptoms of iron deficiency by oral administration of a simple iron salt such as ferrous sulfate and ferrous gluconate. If oral supplementation does not achieve the desired results, consider the use of supplemental administration as the next stage of treatment, with intravenous and intramuscular injections being two common methods of administration.
现已开发了多种注射治疗铁缺乏症的疗法。 为此, FDA批准了两类 化学药物。 第一类为右旋糖酐铁, 为氢氧化铁和葡聚糖的复合物。 一旦 注射进入人体, 右旋糖酐铁迅速被细胞吸收, 并分解成铁及葡聚糖两部 分, 然后进入不同的代谢途径。  A variety of treatments for the treatment of iron deficiency have been developed. To this end, the FDA has approved two types of chemical drugs. The first type is iron dextran, which is a complex of iron hydroxide and dextran. Once injected into the body, iron dextran is rapidly absorbed by the cells and decomposed into iron and dextran, and then enters different metabolic pathways.
由于右旋糖酐铁可在一些患者身上引起严重的副反应, 第二类注射 用补充剂一一铁-糖类复合物,作为治疗铁缺乏症更安全的药物就显得格 外有用。 不似含有多聚葡萄糖结构的右旋糖酐铁, 该铁-糖类复合物不含 多聚单糖。 目前市面上可见到的两类铁-糖类复合物, 均具有结合三价铁 离子的葡萄糖酸盐和 /或蔗糖所形成的骨架结构。 第一类铁-糖类复合物为葡萄糖酸铁钠 -蔗糖复合物 (SFGCS ) 。 SFGCS是一大分子复合物, 表观分子量大于 350,000道尔顿。 相比较而 言, 另一类铁 -糖类复合物则要小得多, 其表观分子量小于 80,000道尔 顿。 该类铁 -糖类复合物在化学上称为氢氧化铁-糖复合物 (FHSC ) 。 Because iron dextran can cause serious side effects in some patients, the second type of supplement, an iron-saccharide complex, is particularly useful as a safer drug for the treatment of iron deficiency. Unlike iron dextran containing a polydextrose structure, the iron-saccharide complex does not contain polymonosaccharides. The two types of iron-saccharide complexes currently available on the market have a skeleton structure formed by gluconate and/or sucrose in combination with ferric ions. The first type of iron-saccharide complex is sodium iron gluconate-sucrose complex (SFGCS). SFGCS is a macromolecular complex with an apparent molecular weight greater than 350,000 Daltons. In comparison, another type of iron-saccharide complex is much smaller, with an apparent molecular weight of less than 80,000 Daltons. Such iron-saccharide complexes are chemically referred to as iron hydroxide-sugar complexes (FHSC).
现有已公开的铁-糖类复合物的制备方法要么缺少最终的干燥步骤, 要么要求额外的纯化步骤, 以在干燥前充分除去辅料。 该额外的纯化步 骤不仅降低了总产率, 而且提高了生产总成本。 因此, 有必要改进工艺, 使该铁-糖类复合物在不除去辅料的情况下, 于反应完成后干燥成粉末。  The prior art methods for preparing iron-saccharide complexes either lack a final drying step or require an additional purification step to adequately remove the excipients prior to drying. This additional purification step not only reduces the overall yield but also increases the total cost of production. Therefore, it is necessary to improve the process so that the iron-saccharide complex is dried into a powder after completion of the reaction without removing the excipient.
在美国药典中对铁-糖类复合物, 尤其是铁-蔗糖复合物中 cr离子的 含量有一定的限量范围,如何控制 cr离子的含量却没有文献报道,我们 在研究铁 -糖类复合物尤其是铁-蔗糖复合物的过程中, 发现通过在制备 铁 -蔗糖复合物的过程中加入 NaCl达到控制 Cr离子含量的目的,从而完 成本发明。 发明内容  In the United States Pharmacopoeia, there is a limited range of cr ion content in iron-saccharide complexes, especially iron-sucrose complexes. How to control the content of cr ions has not been reported in the literature. We are studying iron-saccharide complexes. In particular, in the course of the iron-sucrose complex, it has been found that the purpose of controlling the Cr ion content is achieved by adding NaCl in the process of preparing the iron-sucrose complex, thereby completing the present invention. Summary of the invention
本发明的方法解决了上述问题,提供了一种制备铁-糖类复合物干燥 粉末的方法。 本发明的优点在于使得必需的盐或其他辅料, 这里主要指 无机氯化物, 尤其是 NaCl可以在干燥前加入到铁 -糖类复合物中。  The method of the present invention solves the above problems and provides a method of preparing an iron-saccharide composite dry powder. An advantage of the present invention is that it makes the necessary salts or other excipients, here mainly referred to as inorganic chlorides, especially NaCl which can be added to the iron-saccharide complex prior to drying.
一方面,该铁 -糖类复合物可在反应完成后在无须预先除去盐或其他 辅料的情况下进行干燥。 依此方案, 盐或其他辅料的浓度将在干燥后得 以保持。  In one aspect, the iron-saccharide complex can be dried after the reaction is completed without prior removal of salts or other excipients. According to this scheme, the concentration of salt or other excipients will be maintained after drying.
本方法可适用于 SFGCS 及 FHSC这两类铁-糖类复合物, 以及它们 的衍生物和混合物。 由于铁-糖类复合物在溶液中不稳定, 以干燥粉末的 形式储存和运输这些化合物是有益的。虽然已有多种用于制备这两种铁- 糖类复合物的方法, 但却少有制备该类化合物干燥粉末的方法被公开。  The method is applicable to both iron-saccharide complexes of SFGCS and FHSC, as well as derivatives and mixtures thereof. Since the iron-saccharide complex is unstable in solution, it is advantageous to store and transport these compounds in the form of a dry powder. Although there have been various methods for preparing these two iron-saccharide complexes, few methods for preparing dry powders of such compounds have been disclosed.
可将确定、可重复剂量的必需盐或其他辅料加进最终的干燥产物中。 理论上, 这些非活性成分可在纯的活性药物成分干燥后添加。 然而, 在 干燥前引入这些非活性成分可使这些成分与活性药物成分混合得更均 匀。 在干燥前加入必需的辅料有其优点, 因为该辅料没有无菌要求。 这 一改进意义重大, 因其使得原料药制造商可以将该补血药制成易混合的 粉末, 非专利药制造商可于销售前方便地将该药物粉末复溶于水中。 在 原料药制成以后, 仅需添加纯化水。 由此, 本方法通过去除额外的纯化 操作步骤, 从而降低了出错的可能性。 A defined, repeatable amount of the necessary salt or other excipient can be added to the final dried product. In theory, these inactive ingredients can be added after the pure active pharmaceutical ingredient has dried. However, the introduction of these inactive ingredients prior to drying allows these ingredients to be more homogeneously mixed with the active pharmaceutical ingredients. Evenly. It is advantageous to add the necessary excipients prior to drying because the excipients do not have sterility requirements. This improvement is significant because it allows the drug manufacturer to make the blood-blend into an easily miscible powder, and the generic drug manufacturer can conveniently reconstitute the drug powder in water prior to sale. After the bulk drug is made, only purified water needs to be added. Thus, the method reduces the likelihood of errors by removing additional purification steps.
在一实施方案中, 通过测定反应混合物中的盐含量, 以确定所需加 入的盐或辅料的量。 依本发明之方案, 盐及其它辅料与活性成分即铁- 糖类复合物一起进行干燥。 这里所称的盐主要指无机氯化物, 优选是 NaCL 这一改良的新方法使得原料药制造商能将补血药制成易混合的粉 末, 非专利药制造商可在交货用于临床使用前方便地将该粉末复溶于水 中。  In one embodiment, the amount of salt or excipient that is added is determined by determining the salt content of the reaction mixture. According to the solution of the present invention, the salt and other excipients are dried together with the active ingredient, i.e., the iron-saccharide complex. The salt referred to herein mainly refers to an inorganic chloride, preferably NaCL, which is a new and improved method for the drug manufacturer to make the blood-mixing drug into an easily-mixable powder. The generic drug manufacturer can deliver it for clinical use before delivery. The powder is conveniently reconstituted in water.
本发明的目的是提供一种干燥粉末形式的药物组合物 , 其特征在于 包含有效治疗量的活性药物成分氢氧化铁-糖复合物和至少一种添加剂 以及任选的赋形剂, 其中添加剂可为无机氯化物, 如氯化钾、氯化钠等, 优选氯化钠。 氢氧化铁-糖复合物优选为氢氧化铁-蔗糖复合物或葡萄糖 酸铁钠 -蔗糖复合物。 其中, 氢氧化铁-蔗糖复合物的分子式为 [Na2Fe508(OH).3(H20)]nm(C12H22Ou), 其中 n为 1-30的任一整数, m为 1-360的任一整数。优选 n为 5-20的任一整数, m为 60-240的任一整数。 这里的氢氧化铁 -糖复合物的有效治疗量是指铁的含量按重量计为氢氧 化铁-糖复合物重量的 1-20%,优选为 5-10%,氢氧化铁-糖复合物的剂量 范围为 500mg-4g, 优选 1-3 g, 更优选为 1.5-2g。 It is an object of the present invention to provide a pharmaceutical composition in the form of a dry powder comprising a therapeutically effective amount of an active pharmaceutical ingredient iron hydroxide-saccharide complex and at least one additive and optionally an excipient, wherein the additive As the inorganic chloride such as potassium chloride, sodium chloride or the like, sodium chloride is preferred. The iron hydroxide-sugar complex is preferably an iron hydroxide-sucrose complex or a sodium iron gluconate-sucrose complex. Wherein the formula of the iron hydroxide-sucrose complex is [Na 2 Fe 5 0 8 (OH).3(H 2 0)] n m(C 12 H 22 Ou), wherein n is any integer from 1 to 30 m is any integer from 1-360. Preferably n is any integer from 5 to 20, and m is any integer from 60 to 240. The effective therapeutic amount of the iron hydroxide-sugar complex herein means that the iron content is 1-20% by weight, preferably 5-10% by weight, of the iron hydroxide-sugar complex. The dosage range is from 500 mg to 4 g, preferably from 1 to 3 g, more preferably from 1.5 to 2 g.
在制备本发明的组合物时,添加剂如氯化钠在合成氢氧化铁-糖复合 物之前加入到反应混合物中或在合成氢氧化铁 -糖复合物期间加入,在反 应完成后, 不需分离杂质, 可以将含有反应产物氢氧化铁-糖复合物的反 应混合物直接进行冷冻干燥或喷雾干燥, 优选喷雾干燥。  In the preparation of the composition of the present invention, an additive such as sodium chloride is added to the reaction mixture before the synthesis of the iron hydroxide-sugar complex or during the synthesis of the iron hydroxide-saccharide complex, and after the reaction is completed, no separation is required. Impurities, the reaction mixture containing the reaction product iron hydroxide-sugar complex may be directly subjected to freeze drying or spray drying, preferably spray drying.
本发明的药物组合物中的添加剂如氯化钠的用量根据如下方程 I计 算得到。  The amount of the additive such as sodium chloride in the pharmaceutical composition of the present invention is calculated according to the following Equation I.
方程 I: 1.06%- C 反 ) /35.5, Equation I: 1.06%- C reverse) /35.5,
G 反应液: 良 i G 水: 溶配总水量; G reaction solution: good i G water: total dissolved water;
G »: 蔗糖投料量 G, : 氢氧化铁投料量  G »: Sucrose dosage G, : Ferric hydroxide dosage
G 氢氧化钠投料量 G : 取样时馏出水净重  G Sodium hydroxide feed amount G : Net weight of distilled water at the time of sampling
G 补 补加氯化钠量 C 反应; 反应液铁含量(%) G supplemental sodium chloride amount C reaction; reaction liquid iron content (%)
G 反应液氣:
Figure imgf000005_0001
( % ) ,
G reaction liquid gas:
Figure imgf000005_0001
( % ) ,
所述量均以重量计。  The amounts are all by weight.
本发明的另一目的是提供一种适用于人或动物注射给药的氢氧化铁 Another object of the present invention is to provide an iron hydroxide suitable for injection by a human or an animal.
-糖类复合物的制备方法, 该方法主要包含以下步骤: - a method for preparing a carbohydrate complex, the method comprising the following steps:
至少一种糖或糖的衍生物或它们的混合物与在 OH-离子存在下的 Fe(III)离子和无机氯化物接触。 这里所谓接触是指混合在一起进行化学 反应或不起化学反应。 本方法的反应物在水性介质中发生反应。 本发明 的方法所说的 Fe(m)离子优选以氢氧化铁的形式存在, 而氢氧化铁可由 含水的碱性溶液与含 Fe(III)离子的溶液混合制备得到。  At least one sugar or sugar derivative or a mixture thereof is contacted with Fe(III) ions and inorganic chloride in the presence of OH- ions. The term "contacting" as used herein refers to mixing together for chemical reaction or chemical reaction. The reactants of the process react in an aqueous medium. The Fe(m) ion referred to in the method of the present invention is preferably present in the form of iron hydroxide, and the iron hydroxide can be prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions.
本发明的方法所说的含水的碱性溶液选自氢氧化钠, 碳酸钠和碳酸 氢钠水溶液, 优选碳酸钠或碳酸氢钠。  The aqueous alkaline solution referred to in the process of the present invention is selected from the group consisting of sodium hydroxide, sodium carbonate and aqueous sodium hydrogencarbonate, preferably sodium carbonate or sodium hydrogencarbonate.
根据实际需要, 本发明的方法还可进一步包括将未反应的氯化钠连 同反应产物, 如氢氧化铁-蔗糖复合物一起干燥形成最终产物, 即为粉末 组合物。  The method of the present invention may further comprise, according to actual needs, drying unreacted sodium chloride together with a reaction product, such as an iron hydroxide-sucrose complex, to form a final product, i.e., a powder composition.
在本发明的方法中氯化钠的用量根据上述方程 I计算得到。  The amount of sodium chloride used in the process of the present invention is calculated according to Equation I above.
本发明的再一目的是提供一种适用于人或动物肠道外给药的铁-糖 类复合物的制备方法, 该方法主要包含如下步骤:  A further object of the present invention is to provide a process for the preparation of an iron-saccharide complex suitable for parenteral administration to humans or animals, which method comprises the following steps:
a)接触  a) contact
i ) 至少一种糖或糖的衍生物或它们的混合物, 与  i) at least one sugar or sugar derivative or a mixture thereof, and
ii ) OH'离子存在下的 Fe(III)离子,  Ii) Fe(III) ions in the presence of OH' ions,
b)加入氯化钠; 和 C) 干燥包含铁 -糖类复合物的最终反应混合物, 使其成为粉末形 式。 b) adding sodium chloride; and C) The final reaction mixture comprising the iron-saccharide complex is dried to make it in powder form.
本方法的反应在水性介质中完成, 其中的 Fe(m)离子优选以氢氧化 铁的形式存在, 而氢氧化铁通过含水的碱性溶液与含 Fe(III)离子的溶液 混合制备得到, 其中含水的碱性溶液选自氢氧化钠, 碳酸钠和碳酸氢钠 水溶液, 优选碳酸钠或碳酸氢 ¾。 本方法的最终反应混合物通过冻千法 或喷雾干燥法干燥, 优选喷雾干燥法。 喷雾干燥过程中空气温度大约为 70° C到 100° C, 其中空气的进料速度大约在 30Hz到 50Hz之间, 空 气进入喷雾干燥室前空气的预清洁应达到 100,000级规定, 物料的进料 速度大约在 1Hz到 3Hz之间。 本方法中加入的氯化钠与反应产物, 如氢 氧化铁-蔗糖复合物一起干燥形成干燥粉末制品,所得到的粉末能在给药 之前在适当的溶剂中迅速地复溶。 本方法中氯化钠的用量根据上述方程 I计算得到。  The reaction of the method is carried out in an aqueous medium, wherein the Fe(m) ion is preferably present in the form of iron hydroxide, and the iron hydroxide is prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions, wherein The aqueous alkaline solution is selected from the group consisting of sodium hydroxide, sodium carbonate and aqueous sodium hydrogencarbonate, preferably sodium carbonate or hydrogencarbonate. The final reaction mixture of the process is dried by a freeze or spray drying process, preferably a spray drying process. The air temperature during spray drying is about 70 ° C to 100 ° C, where the air feed rate is between 30 Hz and 50 Hz. The pre-cleaning of air before entering the spray drying chamber should reach 100,000 level. The speed is between approximately 1 Hz and 3 Hz. The sodium chloride added in the process is dried with a reaction product such as an iron hydroxide-sucrose complex to form a dry powder product which can be rapidly reconstituted in a suitable solvent prior to administration. The amount of sodium chloride used in the process is calculated according to Equation I above.
在本发明描述的制备粉末状且混有合适辅料的活性补血药成分 (铁 糖复合物)的方法中, "铁" 离子不仅指溶液中的铁离子, 亦指诸如与羟 基基团复合等其他形式存在的铁离子。 类似地, OPT包括氢氧化铁沉淀 物中的 OH_。  In the method for preparing an active blood-enriching ingredient (iron-saccharide complex) which is powdered and mixed with a suitable excipient, the "iron" ion refers not only to iron ions in a solution, but also to other complexes such as a hydroxyl group. Forms of iron ions. Similarly, OPT includes OH_ in the iron hydroxide precipitate.
"复合物"指分子、铁与某种糖的复合体或聚合体。 "辅料"指任何 无补血活性的分子、 组分、 化合物和复合物。 因此, 广义上的辅料包括 未反应的起始原料、 副产物、 降解产物、 緩冲剂、 稀释剂、 防腐剂以及 盐等。亦可将辅料加入反应混合物中以调节最终产物的化学和 /或物理性 质。 此类辅料亦可称 "添加剂" 或 "赋形剂"。  "Complex" refers to a complex or polymer of molecules, iron and certain sugars. "Auxiliary material" means any molecule, component, compound or complex that has no blood-filling activity. Thus, excipients in a broad sense include unreacted starting materials, by-products, degradation products, buffers, diluents, preservatives, salts, and the like. Excipients can also be added to the reaction mixture to adjust the chemical and/or physical properties of the final product. Such excipients may also be referred to as "additives" or "excipients".
本发明的铁 -糖类复合物可能由糖或其衍生物形成的骨架结构与铁 结合所组成。 本发明的方法可用于制备粉末状的铁 -糖复合物。有用的试 剂至少应包含一种糖以及能提供三价铁离子来源的物质。  The iron-saccharide complex of the present invention may be composed of a skeleton structure formed of a sugar or a derivative thereof and iron. The process of the invention can be used to prepare powdered iron-sugar complexes. A useful reagent should contain at least one sugar and a substance that provides a source of ferric ions.
本发明所说的 "糖"指单糖和低聚糖。 "单糖"指之间无配糖键的单 一糖单位。 包括醛糖, 双 糖, 醛酮糖, 酮糖及双酮糖, 还有脱氧糖和 氨基糖, 以及它们的衍生物。 例如单糖的例子包括二羟基丙酮,甘油醛, 赤藓糖, 核糖, 山梨糖, 戊酪糖, 阿拉伯糖, 左旋糖, 半乳糖和 manose 等。 "低聚糖"指十个以内的单糖结合在一起的糖。低聚糖包括但不局限 于蔗糖, 麦芽糖、 纤维二糖、 异麦芽糖、 龙胆二糖、 蜜二糖、 芸香糖、 樱草糖、 海藻糖、 乳糖和它们的衍生物。 优选的是蔗糖。 The term "sugar" as used in the present invention refers to monosaccharides and oligosaccharides. "Monosaccharide" refers to a single sugar unit without a glycosidic bond. These include aldoses, disaccharides, aldoses, ketoses and diketoses, as well as deoxysaccharides and amino sugars, as well as derivatives thereof. Examples of monosaccharides include dihydroxyacetone, glyceraldehyde, Red sugar, ribose, sorbose, pentose, arabinose, levulose, galactose and manose. "Oligosaccharide" refers to a sugar in which ten or more monosaccharides are combined. Oligosaccharides include, but are not limited to, sucrose, maltose, cellobiose, isomaltose, gentiobiose, melibiose, rutose, primrose, trehalose, lactose, and derivatives thereof. Preferred is sucrose.
"糖衍生物" 指由该单糖或低聚糖衍生的化合物。 包括一个或多个 末端基团被氧化成羧基、 叛基被还原、 一个或多个羟基被氢、 氨基、 硫 氢基等取代的糖。 例如氧化糖包括由葡萄糖氧化得到的葡萄糖酸盐。 基 于它们的电离常数和 pKa值, 这些被氧化的糖基可以离子化。 离子化的 糖被称为蔗糖盐或糖酸, 其质子仍留存在离子化的糖上。 若离子化的羧 基与阳离子如钠离子结合, 就形成了糖酸盐。 其他适合的糖或糖的衍生 物包括那些与上述糖类性质相似的物质。 优选的糖衍生物为葡萄糖酸盐 如葡萄糖酸钠。  "Sugar derivative" means a compound derived from the monosaccharide or oligosaccharide. A sugar comprising one or more terminal groups which are oxidized to a carboxyl group, a thiol group is reduced, and one or more hydroxyl groups are replaced by a hydrogen, an amino group, a sulfhydryl group or the like. For example, oxidized sugars include gluconate salts obtained by oxidation of glucose. These oxidized sugar groups can be ionized based on their ionization constant and pKa value. The ionized sugar is called a sucrose salt or a sugar acid, and its protons remain on the ionized sugar. If the ionized carboxyl group is combined with a cation such as sodium ion, a sugar salt is formed. Other suitable sugar or sugar derivatives include those which are similar in nature to the sugars described above. A preferred sugar derivative is a gluconate such as sodium gluconate.
对本发明有用的典型糖及其衍生物须可充分溶于水中。 包括 D型和 L型光学异构体的糖或其外消旋混合物在内的自然存在或合成的糖及其 衍生物均适用于本发明。 糖的衍生物可能包括基于糖的酸、 盐、 甲酯、 胺和醇衍生物。 酸包括但不局限于葡萄糖酸、 葡萄糖二酸、羟基酸果糖、 α -曱基酪氨酸、 糖醛酸、 趁糖二酸、 甘露酸、 糖酪酸、 半乳糖醛酸、 葡 萄糖醛酸、 甘露糖醛酸、 木糖酸、 酒石酸、 半乳糖二酸、 甘油酸、 乳酸、 阿拉伯糖二羟酸、 甘露糖二羟酸、 葡萄糖二羟酸、 麦芽糖酸以及乳糖醛 酸。 盐可由糖醛酸和碱金属或碱土金属构成, 这些金属包括但不局限于 锂、 钠、 钾、 铍、 镁、 钙、 锶和钡等。 其中尤其有用的盐为葡萄糖酸钠。 胺包括但不局限于岩藻糖胺(2-氨基 -2,6-二脱氧半乳糖)、 半乳糖胺(2- 氨基 -2-脱氧半乳糖)、 acosamine ( 3-氨基 -2,3,6-三脱氧 -L-木-己糖)、 杆 菌胺(2,4-二氨基-2,4,6-三脱氧-0-葡萄糖) 、 葡萄糖胺(2-氨基 -2-脱氧 葡萄糖)等。 醇包括但不局限于甘露醇、 葡糖醇、 阿拉伯糖醇、 木糖醇、 岩藻糖醇、 鼠李糖醇、 赤藓糖醇、 核醣醇、 半乳糖醇、 丙三醇等。  Typical sugars and derivatives thereof useful in the present invention must be sufficiently soluble in water. Naturally occurring or synthetic sugars and derivatives thereof, including the sugars of the D and L optical isomers or their racemic mixtures, are suitable for use in the present invention. Derivatives of sugars may include sugar based acids, salts, methyl esters, amines and alcohol derivatives. Acids include, but are not limited to, gluconic acid, dextrose diacid, hydroxy acid fructose, alpha-mercapto tyrosine, uronic acid, sucrose diacid, mannoic acid, saccharide acid, galacturonic acid, glucuronic acid, mannose Uronic acid, xylic acid, tartaric acid, galactonic acid, glyceric acid, lactic acid, arabinose dihydroxy acid, mannose dihydroxy acid, glucose dihydroxy acid, maltoic acid, and lactanoic acid. The salt may be composed of uronic acid and an alkali metal or alkaline earth metal including, but not limited to, lithium, sodium, potassium, rubidium, magnesium, calcium, strontium and barium. A particularly useful salt therein is sodium gluconate. Amines include, but are not limited to, fucosylamine (2-amino-2,6-dideoxygalactose), galactosamine (2-amino-2-deoxygalactose), acosamine (3-amino-2,3, 6-tripaoxy-L-wood-hexose), bacitracin (2,4-diamino-2,4,6-trideoxy-0-glucose), glucosamine (2-amino-2-deoxyglucose), etc. . Alcohols include, but are not limited to, mannitol, glucose alcohol, arabitol, xylitol, fucitol, rhamitol, erythritol, ribitol, galactitol, glycerol, and the like.
聚合糖或多糖例如淀粉、纤维素、右旋糖酐和糊精不适用于本发明。 事实上, 本发明的铁-糖类复合物不包含显著数量的多糖。对本发明的目 的而言, "显著数量" 被定义为会引起不良反应的多糖浓度, 例如铁-糖 类复合物通过非胃肠道方式用药于患者时引起的过敏反应。 Polymeric sugars or polysaccharides such as starch, cellulose, dextran and dextrin are not suitable for use in the present invention. In fact, the iron-saccharide complex of the present invention does not contain a significant amount of polysaccharide. For the purpose of the present invention In terms of "significant quantity" is defined as the concentration of polysaccharide that causes an adverse reaction, such as an allergic reaction caused by an iron-saccharide complex when administered to a patient parenterally.
因此, 本发明所称的铁-糖类复合物优选为铁-蔗糖复合物或葡萄糖 酸铁钠复合物。  Therefore, the iron-saccharide complex referred to in the present invention is preferably an iron-sucrose complex or a sodium iron gluconate complex.
制备铁-糖类复合物的反应在水相或实际上为水相的环境中进行较 理想。 "实际上为水相" 意味着反应介质的一部分可以包括非水性液体, 在该程度内生成铁-糖类复合物的反应不会受到明显的影响。 更适宜地, 反应介质几乎全部是水。  The reaction for preparing the iron-saccharide complex is preferably carried out in an aqueous phase or an environment which is actually an aqueous phase. "Substantially aqueous phase" means that a portion of the reaction medium can include a non-aqueous liquid, and the reaction to form an iron-saccharide complex within this extent is not significantly affected. More suitably, the reaction medium is almost entirely water.
该铁离子最好为三价铁离子, 而非二价铁离子。 可溶或可分散的含 三价铁的化合物可被用作 Fe(m)的来源材料。 这些材料包括但不限于氯 化铁、 硝酸铁、 硫酸铁、 碳酸铁、 柠檬酸铁以及氢氧化铁等。 氢氧化铁 对本发明尤为有用, 但上述其他的铁盐可用于制备氢氧化铁。 虽然大部 分铁盐都是可用的, 但以那些微溶于水的铁盐为最好。  The iron ion is preferably a ferric ion, not a divalent iron ion. A soluble or dispersible trivalent iron-containing compound can be used as a source material of Fe(m). These materials include, but are not limited to, iron chloride, ferric nitrate, ferric sulfate, iron carbonate, ferric citrate, and iron hydroxide. Iron hydroxide is particularly useful in the present invention, but the other iron salts described above can be used to prepare iron hydroxide. Although most of the iron salts are available, it is best to use iron salts which are slightly soluble in water.
氢氧化铁优选为固体沉淀状态或为分散的胶体状态。 胶体由一种被 分成微小颗粒(胶粒) 的物质分散于另一种物质中而构成。 胶体被认为 是一种介于溶液和混悬液之间的物理状态。 氢氧化铁胶粒的大小在 1纳 米到 100纳米的范围内。 "真溶液" 指两种或多种物质的均质混合物。 在 "真溶液" 中, 溶质的粒度近似于分子的大小, 这比胶体或悬浮液的 颗粒粒度要小很多。 基于本发明, "溶液" 所指的范围较宽, 包括真溶 液和胶体以及它们的混合体。 因此, 反应混合物溶液可指混有溶于 "真 溶液" 中的未反应物质的氢氧化铁胶体。  The iron hydroxide is preferably in a solid precipitated state or in a dispersed colloidal state. The colloid is composed of a substance divided into fine particles (gel particles) dispersed in another substance. A colloid is considered to be a physical state between a solution and a suspension. The size of the ferric hydroxide colloid is in the range of 1 nm to 100 nm. "True solution" means a homogeneous mixture of two or more substances. In "true solution", the particle size of the solute approximates the size of the molecule, which is much smaller than the particle size of the colloid or suspension. Based on the present invention, "solution" refers to a wide range, including true solutions and colloids, and mixtures thereof. Therefore, the reaction mixture solution may refer to an iron hydroxide colloid mixed with an unreacted substance dissolved in a "true solution".
具代表性的, 铁盐的水溶液可用来制备氢氧化铁。 或者, 直接从市 场上购买氢氧化铁。 有多种可水解产生 (OH)-离子的碱或盐可被用来制 备氢氧化铁中间体。 此类碱或盐包括氢氧化钠, 氢氧化钾, 碳酸钠以及 碳酸氢钠。 六水合三氯化铁是 Fe(III)离子的最好来源。 碳酸钠为与铁盐 反应制备氢氧化铁的最好原料。  Typically, an aqueous solution of an iron salt can be used to prepare iron hydroxide. Or, buy iron hydroxide directly from the market. A wide variety of bases or salts which hydrolyze to produce (OH)-ions can be used to prepare iron hydroxide intermediates. Such bases or salts include sodium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydrogencarbonate. Ferric chloride hexahydrate is the best source of Fe(III) ions. Sodium carbonate is the best raw material for the preparation of iron hydroxide by reaction with iron salts.
若通过铁盐与碱或碱性化合物如碳酸钠反应来制备氢氧化铁 , 则可 以固体或溶液的形式混合铁盐与碱或碱性化合物。 最好先将铁盐完全溶 于水中, 再将碳酸钠溶液緩慢滴加到铁盐溶液中。 搅拌 10-30分钟, 即 得氢氧化铁中间体。 该氢氧化铁可直接用于后续与糖的反应中。 将糖以 固体或溶液的形式加入到已分散或呈胶体状态的氢氧化铁中。 If iron hydroxide is prepared by reacting an iron salt with a base or a basic compound such as sodium carbonate, the iron salt and the base or basic compound may be mixed in the form of a solid or a solution. It is best to completely dissolve the iron salt first. In water, the sodium carbonate solution was slowly added dropwise to the iron salt solution. Stirring for 10-30 minutes gives the iron hydroxide intermediate. The iron hydroxide can be used directly in the subsequent reaction with sugar. The sugar is added as a solid or a solution to the iron hydroxide which has been dispersed or colloidal.
基于本发明, 反应最好以离心分离结束, 并用水洗涤, 收集滤饼。 氢氧化铁最好是以水洗, 以利于测定其重量。 测定湿氢氧化铁的含水量 是为了测定氢氧化铁的净重。 在有水存在的情况下, 将固体或溶液形式 的糖与氢氧化铁混合。 滴加一定量的氢氧化钠溶液以调节反应液的 pH 值。 搅拌反应物并緩慢加热以促进溶解。 糖、 水和氢氧化钠的投料量基 于所加氢氧化铁的量计算。  Based on the present invention, the reaction is preferably terminated by centrifugation and washed with water to collect the filter cake. The iron hydroxide is preferably washed with water to facilitate determination of its weight. The water content of the wet iron hydroxide was measured to determine the net weight of the iron hydroxide. The sugar in the form of a solid or solution is mixed with iron hydroxide in the presence of water. A certain amount of sodium hydroxide solution was added dropwise to adjust the pH of the reaction solution. The reaction was stirred and heated slowly to promote dissolution. The amount of sugar, water and sodium hydroxide charged is calculated based on the amount of iron hydroxide added.
投料比 (w/w ) 为:  The feed ratio (w/w) is:
氢氧化铁 : 蔗糖 : 氢氧化钠 : 总水 =1: a : b : c  Iron hydroxide : sucrose : sodium hydroxide : total water =1: a : b : c
其中:  among them:
a为 5-12范围内的任一数字, a在 8-9之间更为可取; b为 0.1-0.3之间的任一数字, b在 0.15-0.25之间更为可取; c为 10-15之间的任一数字, c在 12-13之间更为可取。 氢氧化铁 (干品)的重量 =氢氧化铁中间体的重量 X氢氧化铁中间 体的铁含量 X 106.86/55.84  a is any number in the range 5-12, a is preferably between 8-9; b is any number between 0.1-0.3, b is preferably between 0.15-0.25; c is 10- Any number between 15 and c is preferable between 12-13. Weight of iron hydroxide (dry) = weight of iron hydroxide intermediate X iron content of iron hydroxide intermediate X 106.86/55.84
在本发明中氢氧化铁中间体是指氢氧化铁的湿品 (含水的氢氧化 铁)。  In the present invention, the iron hydroxide intermediate means a wet product of iron hydroxide (aqueous iron hydroxide).
本发明在一实例中的投料比 (w/w ) 为:  The feed ratio (w/w) in one example of the present invention is:
氢氧化铁 : 蔗糖 : 氢氧化钠 : 总水 =1 : 8.4906 : 0.2076 : 12.2642 总水包括氢氧化铁中间体的水, 其相当于中间体总重减去氢氧化铁 净重。 总水还包括氢氧化钠溶液和其他溶液中的水。  Iron hydroxide: sucrose: sodium hydroxide: total water = 1: 8.4906: 0.2076: 12.2642 The total water comprises water of the iron hydroxide intermediate, which corresponds to the total weight of the intermediate minus the net weight of the iron hydroxide. The total water also includes sodium hydroxide solution and water from other solutions.
在所有的成分都已完全溶解后, 应对该溶液取样检测氯和铁含量用 以确定所需加入的氯化钠的重量。 氯化钠的重量通过下式计算得到 方程 I:  After all ingredients have been completely dissolved, the solution should be sampled for chlorine and iron content to determine the weight of sodium chloride to be added. The weight of sodium chloride is calculated by the following equation:
G 反应液 = G 总水 + ( 蔗糖 + G〗 + G 氢 化钠― G 馏出水 G Reaction solution = G total water + (sucrose + G) + G sodium hydride - G distillate
G 补氯 == G 反应波 x 58.5 X (C 反应液饮 X 1.06%- C 反应液氣) /35·5, G 反应液: 反应液总量 G 总水: 溶配总水量; G supplemental chlorine == G reaction wave x 58.5 X (C reaction solution X 1.06% - C reaction liquid gas) /35·5, G reaction solution: total amount of reaction solution G total water: total amount of dissolved water;
G «: 蔗糖投料量 G,: 氢氧化铁投料量  G «: Sucrose dosage G,: Ferric hydroxide dosage
G 氢氧化钠投料量 G it水: 取样时馏出水净重 G Sodium hydroxide feed amount G it water: Net weight of distilled water during sampling
G ^: 补加氯化钠量 C 反应液 反应液铁含量(% ) G ^: Additional sodium chloride amount C Reaction liquid Reaction liquid iron content (%)
C 反应液氯含量(%) , C reaction liquid chlorine content (%),
所述量均以重量计。  The amounts are all by weight.
氯化钠的加入量是依据上述计算公式得到的。  The amount of sodium chloride added is obtained according to the above calculation formula.
总的反应混合物被过滤, 同时滤液在 100°C至 120°C得以蒸馏。蒸馏 罐的温度和反应混合物的浊点都应被监控。 当浊点到达一设定值, 即 4.6-5.1之间任一值时, 停止蒸馏。 当反应混合物还艮热的时候加入少量 的水。 搅动反应混合物然后检测其溶液比重。 如果其比重在 1.35 g/ml 以上, 再加水直到溶液比重在 1.25-1.35 g/ml之间。 制得的铁-蔗糖溶液 经冷却后待干燥。  The total reaction mixture was filtered while the filtrate was distilled at 100 ° C to 120 ° C. The temperature of the distillation tank and the cloud point of the reaction mixture should be monitored. When the cloud point reaches a set value, which is any value between 4.6 and 5.1, the distillation is stopped. A small amount of water was added while the reaction mixture was still hot. The reaction mixture was agitated and then the specific gravity of the solution was measured. If the specific gravity is above 1.35 g/ml, add water until the specific gravity of the solution is between 1.25-1.35 g/ml. The prepared iron-sucrose solution was cooled and dried.
在干燥前不必移出未反应的反应物或反应副产物。 同时也可使用其 他的干燥方法干燥最终产物,最终的铁 -蔗糖溶液用喷雾干燥法干燥更为 可取。 压缩空气和热空气的预清洁应达到 100,000级的标准。 在干燥过 程中, 干燥器中的物料应成流化状。 流化的液体先通过蠕动移液泵, 然 后通过压缩空气雾化成极细的液滴, 再通过喷雾器喷射进入干燥器。 热 空气也用来促进干燥。  It is not necessary to remove unreacted reactants or reaction by-products prior to drying. The final product can also be dried using other drying methods, and the final iron-sucrose solution is preferably dried by spray drying. Pre-cleaning of compressed air and hot air should reach the 100,000 level. During the drying process, the material in the dryer should be fluidized. The fluidized liquid is first passed through a peristaltic pipetting pump and then atomized into a very fine droplet by compressed air and then injected into the dryer through a sprayer. Hot air is also used to promote drying.
干燥参数如下: 物料输入速度在 l-3Hz之间。 空气温度大约为 70。C 到 100。C。 物料温度大约为 50。C到 75。C。 空气输入速度为 30-50Hz。  The drying parameters are as follows: The material input speed is between l-3Hz. The air temperature is approximately 70. C to 100. C. The material temperature is approximately 50. C to 75. C. The air input speed is 30-50Hz.
干燥后的物料经冷却后称重。最好把干燥的铁-蔗糖复合物粉碎再通 过 40 目筛。 过筛后的复合物最好再混合以得到均匀的铁-蔗糖复合物粉 末。 把干燥粉末状的复合物装入到具两层的 PE袋中, 然后密封。 把密 封好的 PE袋放入到铝塑复合袋中密封, 再放入到铝听中, 密封, 贴签。 千燥的铁-蔗糖复合物可以包装成 10kg, 5kg, lkg, 500g, 250g, 50g的 规格, 或者按照顾客的需要进行包装。 提供的化学制品,化合物和投料量的范围只是作为一个大体的指导。 例如, 这里所用的糖类中的蔗糖其目的仅仅是为了便于阐述。 本领域技 术人员有可能找出其他类似的化学制品或范围, 这些化学制品或范围能 在不偏离本发明实质的情况下完成该生产过程。 具体实施方式 The dried material was cooled and weighed. Preferably, the dried iron-sucrose complex is comminuted through a 40 mesh screen. The screened composite is preferably remixed to obtain a uniform iron-sucrose complex powder. The dry powdered composite was loaded into a two-layer PE bag and then sealed. Put the sealed PE bag into the aluminum-plastic composite bag and seal it, then put it into the aluminum to listen, seal and label. The dry iron-sucrose complex can be packaged in 10kg, 5kg, lkg, 500g, 250g, 50g or packaged according to customer needs. The range of chemicals, compounds, and amounts supplied is provided as a general guide. For example, the sucrose in the saccharides used herein is for illustrative purposes only. It is possible for a person skilled in the art to find other similar chemicals or ranges that can be completed without departing from the spirit of the invention. detailed description
以下实施例用以解释和理解本发明的技术方案,但不用于限制本发 明的范围。  The following examples are intended to explain and understand the technical solutions of the present invention, but are not intended to limit the scope of the invention.
实施例 1 Example 1
氢氧化铁中间体的制备:  Preparation of iron hydroxide intermediates:
称取无水碳酸钠 9.30g, 加入到 100g纯化水中溶解。 另称取六水合 三氯化铁 14.50g, 加入到 60g純化水中, 搅拌溶解。 三氯化铁溶解完全 后,将制好的碳酸钠溶液加入到三氯化铁溶液中。碳酸钠溶液加入完毕, 继续搅拌一段时间, 用离心机离心、 用纯化水洗涤。 收集沉淀, 即得氢 氧化铁中间体。  Anhydrous sodium carbonate 9.30 g was weighed and dissolved in 100 g of purified water. Another weighed 14.50g of ferric chloride hexahydrate, added to 60g of purified water, stirred and dissolved. After the ferric chloride is completely dissolved, the prepared sodium carbonate solution is added to the ferric chloride solution. After the sodium carbonate solution is added, stirring is continued for a while, centrifuged with a centrifuge, and washed with purified water. The precipitate is collected to obtain an iron hydroxide intermediate.
铁-蔗糖复合物的制备:  Preparation of iron-sucrose complex:
按下述比例在烧瓶中投入反应物:  The reactants were placed in the flask in the following proportions:
氢氧化铁: 蔗糖: 氢氧化钠: 溶配总水 =5.4g: 50g: l.Og: 75g, 緩慢加热升温; 当物料溶解完全后, 取样检测氯含量和铁含量,取 样后重新启动搅拌, 继续加热。 根据检测结果按上述方程 I计算补加氯 化钠的量, 称量计算好的氯化钠补加量, 加入反应液中。 补加氯化钠后, 停止加热。 反应温度控制在 100〜120°C之间; 边蒸馏边反应, 直至浊点 达到 4.6~5.1之间时反应结束。  Iron hydroxide: Sucrose: Sodium hydroxide: Dissolved total water = 5.4g: 50g: l.Og: 75g, slowly heated to warm up; When the material is completely dissolved, sample and check the chlorine content and iron content, and restart stirring after sampling. Continue to heat. According to the test results, the amount of sodium chloride added was calculated according to the above equation I, and the calculated amount of sodium chloride was weighed and added to the reaction liquid. After adding sodium chloride, stop heating. The reaction temperature is controlled between 100 and 120 ° C; the reaction is carried out while distilling until the cloud point reaches between 4.6 and 5.1 and the reaction is completed.
实施例 2 Example 2
冷冻干燥制备铁-蔗糖复合物的固体粉末  Free-drying preparation of solid powder of iron-sucrose complex
取实施例 1 所得到的铁 -蔗糖复合物溶液, 加入纯化水至比重为 1.26g/ml, 置于不锈钢托盘中, 放入冻干机中, 真空冷冻干燥 30小时, 即得到易溶于水的棕褐色的粉末,该粉末状组合物含有预定量的氯离子。 实施例 3 The iron-sucrose complex solution obtained in Example 1 was added, purified water was added to a specific gravity of 1.26 g/ml, placed in a stainless steel tray, placed in a lyophilizer, and vacuum-dried for 30 hours to obtain a water-soluble solution. A tan powder containing a predetermined amount of chloride ions. Example 3
称取无水碳酸钠 139.5g, 加入到 1500g纯化水中溶解。 另称取六水 合三氯化铁 217.5g, 加入到 900g纯化水中,搅拌溶解。 三氯化铁溶解完 全后,将制好的碳酸钠溶液加入三氯化铁溶液中, 然后搅拌 10分钟, 用 离心机离心、 用纯化水洗涤。 收集沉淀, 即得中间体氢氧化铁。  Anhydrous sodium carbonate 139.5 g was weighed and dissolved in 1500 g of purified water. Further, 217.5 g of ferric chloride hexahydrate was added, and it was added to 900 g of purified water, and stirred to dissolve. After the ferric chloride was dissolved, the prepared sodium carbonate solution was added to the ferric chloride solution, and then stirred for 10 minutes, centrifuged with a centrifuge, and washed with purified water. The precipitate is collected to obtain the intermediate iron hydroxide.
按下述比例将反应物加入烧瓶中: 氢氧化铁: 蔗糖: 氢氧化钠: 溶 配总水 = 79.5g: 755.2 g: 19.9 g: 975g, 緩慢加热升温; 当物料溶解完 全后, 取样检测氯含量和铁含量,取样后重新启动搅拌, 继续加热。 根 据检测结果按上述方程 I计算补加氯化钠的量, 称量计算好的氯化钠补 加量, 加入反应液中。 保持温度在 100-12(TC, 浊点达到 5.0时, 反应到 达终点。  The reactants were added to the flask in the following proportions: Iron hydroxide: Sucrose: Sodium hydroxide: Total dissolved water = 79.5 g: 755.2 g: 19.9 g: 975 g, slowly heated to warm up; The content and the iron content, restart the stirring after sampling, and continue to heat. According to the test results, the amount of sodium chloride added is calculated according to the above equation I, and the calculated amount of sodium chloride is weighed and added to the reaction liquid. Keep the temperature at 100-12 (TC, when the cloud point reaches 5.0, the reaction reaches the end point.
在所得的铁-蔗糖复合物溶液中加入纯化水调节比重到 1.33g/ml, 进 行喷雾干燥,控制进液速度 1.0HZ、进风温度 70 ~ 100 °C、物料温度 50 ~ 75°C。 最后得到棕褐色的粉末, 该粉末状组合物含有预定量的氯离子。 实施例 4  Purified water was added to the obtained iron-sucrose complex solution to adjust the specific gravity to 1.33 g/ml, and spray-drying was carried out to control the inlet speed of 1.0 HZ, the inlet air temperature of 70 to 100 ° C, and the material temperature of 50 to 75 °C. Finally, a tan powder is obtained which contains a predetermined amount of chloride ions. Example 4
氢氧化铁中间体的制备 Preparation of iron hydroxide intermediate
称取无水碳酸钠 9.30kg, 加入到 100kg纯化水中, 搅拌溶解后抽入 计量罐。 称取六水合三氯化铁 14.50kg, 加入到 60kg纯化水中, 搅拌溶 解。三氯化铁溶解完全后,将制好的碳酸钠溶液滴加入三氯化铁溶液中, 加料时间控制在 30分钟左右。碳酸钠溶液滴加完毕,继续搅拌一段时间, 生成的料液用离心机甩滤、 用纯化水洗涤。 收集滤饼, 即得氢氧化铁中 间体。  Weigh 9.30 kg of anhydrous sodium carbonate, add to 100 kg of purified water, stir and dissolve, and then pump into the measuring tank. 14.50 kg of ferric chloride hexahydrate was weighed, added to 60 kg of purified water, and dissolved by stirring. After the ferric chloride is completely dissolved, the prepared sodium carbonate solution is added dropwise to the ferric chloride solution, and the feeding time is controlled to about 30 minutes. After the sodium carbonate solution was added dropwise, stirring was continued for a while, and the resulting solution was filtered with a centrifuge and washed with purified water. The filter cake is collected to obtain an iron hydroxide intermediate.
铁 -蔗糖复合物原液的制备: Preparation of iron-sucrose complex stock solution:
投料比 (重量):  Feeding ratio (weight):
氢氧化铁: 蔗糖: 氢氧化钠: 溶配总水 =5.3kg: 45kg: 1.1kg: 65kg 按上述比例称取蔗糖、 溶配补加水和氢氧化钠; 从溶配补加水中, 取适量的纯化水溶解氢氧化钠; 向溶配罐中依次加入溶配补加水、蔗糖、 中间体; 开启搅拌; 然后加入氢氧化钠溶液, 封闭加料口。 緩慢加热升 温; 当物料溶解完全后, 取样检测氯含量和铁含量, 取样后重新启动搅 拌, 继续加热。 根据检测结果按上述方程 I计算补加氯化钠的量, 称量 计算好的氯化钠补加量, 加入反应液中。 控制加热蒸汽压力, 反应温度 控制在 100~120°C之间; 边蒸馏边反应。 在浊点达到 5.0时, 反应到达 终点。 当反应达到终点时, 加入适量纯化水稀释, 溶液比重调节在 1.25~1.35g/ml之间。 Iron hydroxide: sucrose: sodium hydroxide: dissolved total water = 5.3kg: 45kg: 1.1kg: 65kg Weigh sucrose, dissolved water and sodium hydroxide according to the above ratio; from the dissolved water, take the appropriate amount The purified water dissolves the sodium hydroxide; the dissolved water, sucrose, and the intermediate are sequentially added to the solution tank; the stirring is turned on; then the sodium hydroxide solution is added to close the feed port. Slow heating Temperature; When the material is completely dissolved, sample and check the chlorine content and iron content, restart the stirring after sampling, and continue heating. According to the test result, the amount of additional sodium chloride is calculated according to the above equation I, and the calculated amount of sodium chloride is calculated and added to the reaction liquid. The heating steam pressure is controlled, and the reaction temperature is controlled between 100 and 120 ° C; the reaction is carried out while distilling. When the cloud point reached 5.0, the reaction reached the end point. When the reaction reaches the end point, it is diluted with an appropriate amount of purified water, and the specific gravity of the solution is adjusted between 1.25 and 1.35 g/ml.
喷雾干燥: Spray drying:
铁-蔗糖复合物原液采取喷雾干燥的方式进行干燥,干燥过程使用的 压缩空气及热空气均要净化处理并达到十万级洁净度的要求。 为了防止 细颗粒或细粉被抽入空气, 对外界形成污染, 干燥机上部装有捕集袋。  The iron-sucrose complex stock solution is dried by spray drying, and the compressed air and hot air used in the drying process are purified and up to the requirements of 100,000 cleanliness. In order to prevent fine particles or fine powder from being drawn into the air and causing pollution to the outside, a trap bag is placed on the upper portion of the dryer.
控制进液速度 1.0 ~ 3.0HZ, 进风温度 70 ~ 100 °C、 物料温度 50 ~ 75 °C和主风机频率 30 ~ 50HZ, 干燥物料先粉碎, 再过筛, 混合, 用双层 聚乙烯塑料袋盛装。  Control the liquid inlet speed of 1.0 ~ 3.0HZ, the inlet air temperature of 70 ~ 100 °C, the material temperature of 50 ~ 75 °C and the main fan frequency of 30 ~ 50HZ, the dry material is first crushed, then sieved, mixed, with double-layer polyethylene plastic Bags are packed.

Claims

权 利 要 求 Rights request
1. 一种粉末药物组合物, 其特征在于: 包含有效治疗量的活性药物 成分铁-糖类复合物和至少一种添加剂以及任选的赋形剂,其中所述添加 剂为无机氯化物。 A powder pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient iron-saccharide complex and at least one additive and optionally an excipient, wherein the additive is an inorganic chloride.
2. 权利要求 1的药物组合物, 其中所述铁-糖类复合物选自氢氧化 铁-蔗糖复合物和葡萄糖酸铁钠 -蔗糖复合物。  2. The pharmaceutical composition of claim 1, wherein the iron-saccharide complex is selected from the group consisting of a ferric hydroxide-sucrose complex and a sodium iron gluconate-sucrose complex.
3. 权利要求 1或 2的药物组合物, 其中所述无机氯化物为氯化钠。 3. The pharmaceutical composition according to claim 1 or 2, wherein the inorganic chloride is sodium chloride.
4. 权利要求 3 的药物组合物, 其中氯化钠的用量根据如下方程 I 计算得到: 4. The pharmaceutical composition of claim 3, wherein the amount of sodium chloride is calculated according to the following equation I:
方程 I:  Equation I:
G 反应液 = G 总水 + G 蔗糖 + Gi + G 氮 化钠― G 馏出水  G Reaction Solution = G Total Water + G Sucrose + Gi + G Sodium Nitride - G Distillate
G 补氣 = G反应液 x 58.5 X (C 反应液铁 1.06%- C 反应液氣) /35·5, G qi = G reaction solution x 58.5 X (C reaction solution iron 1.06% - C reaction liquid gas) / 35 · 5,
其中:  among them:
G 反 反应液总量 G ^: 溶配总水量;  G total amount of reaction solution G ^: total amount of dissolved water;
G m: 蔗糖投料量 G1 : 氢氧化铁投料量 G m: sucrose feed amount G 1 : ferric hydroxide feed amount
G 氪氣 : 氢氧化钠投料量 G 水: 取样时馏出水净重  G Helium: Sodium hydroxide feed G Water: Net weight of distilled water during sampling
G 补^ 补加氯化钠量 C 反应液铁. 反应液铁含量(%) G Supplement ^ Additional sodium chloride amount C Reaction liquid iron. Reaction liquid iron content (%)
C : 反应液氯含量(%), C : chlorine content (%) of the reaction solution,
所述量均以重量计。  The amounts are all by weight.
5. —种适用于人或动物注射给药的铁-糖类复合物组合物的制备方 法, 包含:  5. A method for preparing an iron-saccharide complex composition suitable for human or animal injection administration, comprising:
i )至少一种糖或糖的衍生物或它们的混合物, 与  i) at least one sugar or sugar derivative or a mixture thereof, and
ϋ )在 ΟΙ 离子存在下的 Fe(III)离子和无机氯化物接触。  ϋ) Fe(III) ions in contact with inorganic chloride in the presence of cerium ions.
6. 权利要求 5的方法, 其中所述的接触在水性介质中进行。  6. The method of claim 5 wherein said contacting is carried out in an aqueous medium.
7.权利要求 5 的方法, 其中所述无机氯化物在合成铁 -糖类复合物 之前加入到反应混合物中或在合成铁 -糖类复合物期间加入。  The method of claim 5, wherein the inorganic chloride is added to the reaction mixture prior to the synthesis of the iron-saccharide complex or during the synthesis of the iron-saccharide complex.
8. 权利要求 5的方法, 其中 Fe(m)以氢氧化铁的形式存在。 8. The method of claim 5 wherein Fe(m) is present in the form of iron hydroxide.
9. 权利要求 8的方法,其中氢氧化铁通过含水的碱性溶液与含 Fe(III) 离子的溶液混合制备得到。 9. The method of claim 8 wherein the iron hydroxide is prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions.
10. 权利要求 9的方法, 其中含水的碱性溶液选自氢氧化钠, 碳酸 钠和碳酸氢钠水溶液。  10. The method of claim 9 wherein the aqueous alkaline solution is selected from the group consisting of sodium hydroxide, sodium carbonate and aqueous sodium hydrogencarbonate.
11. 权利要求 10的方法, 其中含水的碱性溶液为碳酸钠水溶液。 11. The method of claim 10, wherein the aqueous alkaline solution is an aqueous solution of sodium carbonate.
12. 权利要求 10的方法, 其中含水的碱性溶液为碳酸氢钠水溶液。12. The method of claim 10, wherein the aqueous alkaline solution is an aqueous solution of sodium hydrogencarbonate.
13. 权利要求 5的方法, 进一步包括将未反应的无机氯化物连同反 应产物铁 -糖类复合物一起干燥的步骤。 13. The method of claim 5, further comprising the step of drying the unreacted inorganic chloride together with the reaction product iron-saccharide complex.
14.权利要求 5的方法, 其中无机氯化物为氯化钠, 其用量根据如 下方程 I计算得到:  14. The method of claim 5 wherein the inorganic chloride is sodium chloride and the amount is calculated according to Equation I below:
方程 I:  Equation I:
G反应液 = G 总水 + G 蔗糖 + + G 氮¾_化钠― G馏出水  G reaction solution = G total water + G sucrose + + G nitrogen 3⁄4_ sodium - G distillate
G 补氣 = G反应液 x 58.5 X (C 反应液& x 1.06%- C 反应液氣) /35.5, G qi = G reaction solution x 58.5 X (C reaction solution & x 1.06% - C reaction liquid gas) / 35.5,
其中:  among them:
G ^¾: 反应液总量 G 溶配总水量; G ^ 3⁄4 : total amount of reaction solution G dissolved total water amount;
G絲: 蔗糖投料量 G1 : 氢氧化铁投料量 G wire: sucrose feed amount G 1 : iron hydroxide feed amount
G 氢氧化钠投料量 G饱出水: 取样时馏出水净重  G Sodium hydroxide feed amount G saturated water: Net weight of distilled water during sampling
G A: 补加氯化钠量 C 反应液铁. 反应液铁含量(%)G A : Additional sodium chloride amount C Reaction liquid iron. Reaction liquid iron content (%)
C 反应 反应液氯含量(%) , C reaction reaction liquid chlorine content (%),
所述量均以重量计。  The amounts are all by weight.
15.权利要求 5的方法, 其中所述糖或糖的衍生物选自蔗糖和葡萄 糖酸钠。  15. The method of claim 5, wherein the sugar or sugar derivative is selected from the group consisting of sucrose and sodium gluconate.
16. 一种适用于人或动物肠道外给药的铁-糖类复合物组合物的制 备方法, 包含:  16. A method of preparing an iron-saccharide complex composition suitable for parenteral administration to a human or animal, comprising:
a)接触  a) contact
i ) 至少一种糖或糖的衍生物或它们的混合物, 与  i) at least one sugar or sugar derivative or a mixture thereof, and
ii ) OH-离子存在下的 Fe(III)离子;  Ii) Fe(III) ions in the presence of OH- ions;
b)加入氯化钠; 和 C) 干燥包含铁 -糖类复合物的最终反应混合物, 使其成为粉末形式。b) adding sodium chloride; and C) The final reaction mixture comprising the iron-saccharide complex is dried to make it in powder form.
17. 权利要求 16的方法, 其中步骤 (a)在水性介质中完成。 17. The method of claim 16 wherein step (a) is accomplished in an aqueous medium.
18. 权利要求 16的方法,其中 Fe(III)基本上以氢氧化铁的形式存在。 18. The method of claim 16 wherein Fe(III) is present substantially in the form of iron hydroxide.
19. 权利要求 18 的方法, 其中氢氧化铁通过含水的碱性溶液与含 Fe(III)离子的溶液混合制备得到。 19. The method of claim 18, wherein the iron hydroxide is prepared by mixing an aqueous alkaline solution with a solution containing Fe(III) ions.
20. 权利要求 19的方法, 其中含水的碱性溶液选自氢氧化钠, 碳酸 钠, 碳酸氢钠或其混合物。  20. The method of claim 19, wherein the aqueous alkaline solution is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium hydrogencarbonate or mixtures thereof.
21. 权利要求 20的方法,其中含水的碱性溶液选自碳酸钠和碳酸氢 钠。  21. The method of claim 20 wherein the aqueous alkaline solution is selected from the group consisting of sodium carbonate and sodium bicarbonate.
22. 权利要求 16的方法,其中最终反应混合物通过冻干法或喷雾干 燥法干燥。  22. The method of claim 16 wherein the final reaction mixture is dried by lyophilization or spray drying.
23.权利要求 16的方法,其中加入的氯化钠和步骤 a)的反应产物一 起干燥形成干燥粉末制品。  23. The method of claim 16 wherein the added sodium chloride and the reaction product of step a) are dried together to form a dry powder product.
24. 权利要求 16的方法,其中氯化钠的用量根据如下方程 I计算得 到:  24. The method of claim 16 wherein the amount of sodium chloride is calculated according to Equation I below:
方程 I:  Equation I:
G 反应液 = G 总水 + G 蔗糖 + + G 氛氡化钠― G馏出水  G reaction solution = G total water + G sucrose + + G sodium sulphate - G distillate
G 补氣 = G 反应液 x 58.5 X (C 反应液块 x 1.06%- C 反应液氯) /35.5, G qi = G reaction solution x 58.5 X (C reaction block x 1.06% - C reaction liquid chlorine) / 35.5,
其中:  among them:
G 反应液总量 G . : 溶配总水量;  G Total amount of reaction solution G . : Total dissolved water amount;
G ^: 蔗糖投料量 G1 : 氢氧化铁投料量 G ^: sucrose dosage G 1 : ferric hydroxide dosage
: 氢氧化钠投料量 G ¾出水: 取样时馏出水净重 : Sodium hydroxide feed amount G 3⁄4 effluent: Net weight of distilled water during sampling
G 补 补加氯化钠量 C 反应液铁. 反应液铁含量(%) G supplemental sodium chloride amount C reaction liquid iron. reaction liquid iron content (%)
C 反应液氯含量(%), C reaction liquid chlorine content (%),
所述量均以重量计。  The amounts are all by weight.
25. 权利要求 16 的方法, 其中所述糖或糖的衍生物选自蔗糖、 葡 萄糖酸钠。  25. The method of claim 16 wherein the sugar or sugar derivative is selected from the group consisting of sucrose, sodium gluconate.
PCT/CN2005/002056 2005-11-30 2005-11-30 Iron-saccharide complexs easy to reconstitute and the method for manufacture them WO2007062546A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/002056 WO2007062546A1 (en) 2005-11-30 2005-11-30 Iron-saccharide complexs easy to reconstitute and the method for manufacture them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2005/002056 WO2007062546A1 (en) 2005-11-30 2005-11-30 Iron-saccharide complexs easy to reconstitute and the method for manufacture them

Publications (1)

Publication Number Publication Date
WO2007062546A1 true WO2007062546A1 (en) 2007-06-07

Family

ID=38091851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2005/002056 WO2007062546A1 (en) 2005-11-30 2005-11-30 Iron-saccharide complexs easy to reconstitute and the method for manufacture them

Country Status (1)

Country Link
WO (1) WO2007062546A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117225A1 (en) 2010-03-23 2011-09-29 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
WO2012130882A1 (en) 2011-03-29 2012-10-04 Vifor (International) Ag Fe(iii) complexes for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
WO2012163938A1 (en) 2011-05-31 2012-12-06 Vifor (International) Ag Fe(iii) 2,4-dioxo-1-carbonyl complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
WO2014096193A1 (en) 2012-12-21 2014-06-26 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemia
EP3578182A1 (en) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693211B2 (en) * 2002-05-15 2004-02-17 Geneva Pharmaceuticals, Inc. Chemical process
US20040038930A1 (en) * 2000-11-02 2004-02-26 Chromaceutical Advanced Technologies, Method for producing purified hematinic iron-saccharidic complex and product produced
US6773211B2 (en) * 2001-05-18 2004-08-10 Novator Ab Orbital drilling cutting tool

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038930A1 (en) * 2000-11-02 2004-02-26 Chromaceutical Advanced Technologies, Method for producing purified hematinic iron-saccharidic complex and product produced
US6773211B2 (en) * 2001-05-18 2004-08-10 Novator Ab Orbital drilling cutting tool
US6693211B2 (en) * 2002-05-15 2004-02-17 Geneva Pharmaceuticals, Inc. Chemical process

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117225A1 (en) 2010-03-23 2011-09-29 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
WO2012130882A1 (en) 2011-03-29 2012-10-04 Vifor (International) Ag Fe(iii) complexes for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
WO2012163938A1 (en) 2011-05-31 2012-12-06 Vifor (International) Ag Fe(iii) 2,4-dioxo-1-carbonyl complexes for treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
WO2014096193A1 (en) 2012-12-21 2014-06-26 Vifor (International) Ag Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemia
EP3578182A1 (en) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions
WO2019233867A1 (en) * 2018-06-05 2019-12-12 Bayer Animal Health Gmbh Formulations containing triazinones and iron with a low amount of free iron ions
CN112165946A (en) * 2018-06-05 2021-01-01 拜耳动物保健有限责任公司 Formulations containing triazineone and iron with small amounts of free iron ions

Similar Documents

Publication Publication Date Title
JP4945240B2 (en) Synthesis of high molecular weight iron saccharide complex
US4877778A (en) Method of enhancing lipophile transport using cyclodextrin derivatives
CN104530263B (en) A kind of preparation method of gallic acid bagasse xylan ester
MXPA05004300A (en) Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes.
JPH01503548A (en) heparin derivative
WO1980002798A1 (en) Antithrombin preparation and process for obtaining same
WO2007062546A1 (en) Iron-saccharide complexs easy to reconstitute and the method for manufacture them
WO2008156250A1 (en) Sustained-release chitosan capsules comprising chitosan and phytic acid
CN103768020A (en) Compound taxol lipidosome combined drug, and large-scale industrial production process and application thereof
JP2002507582A (en) Iron-dextran compound for use as a component of a therapeutic composition for the prevention or treatment of iron deficiency, a method for producing said iron-dextran compound, and use of said compound for producing a parenterally administrable therapeutic composition
CN111529493A (en) Amoxicillin soluble powder easy to dissolve in water and high in stability and preparation method thereof
KR840001798B1 (en) Method for the controlled release administration
PT1492821E (en) Iron dextrin compounds for the treatment of iron deficiency anaemia
CN103211825B (en) Novel celecoxib composition and preparation process thereof
WO2006049739A1 (en) Method for treating bacterial infections in horses or pigs with tilmicosin
EP1663258A2 (en) Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans
CN100494368C (en) Sialic acid oligose-chitosan complex, and its preparing method and use
JP2021534193A (en) Oligosaccharide composition and its use for lowering ammonia levels
JP6980018B2 (en) Oligosaccharides that inhibit the endogenous tennase complex, their production methods and uses
WO1997041894A1 (en) Micellar aqueous composition and method for solubilizing hydrophobic drug
CN104814949B (en) Improve chlorogenic acid acylate and the application of chlorogenic acid bioavilability
CN110960491B (en) Preparation method and application of tanshinone IIA-loaded water-soluble chitosan/gamma-polyglutamic acid nano-composite
CN104721153B (en) Injection aminomethylbenzoic acid freeze-drying powder-injection pharmaceutical composition
JP7384822B2 (en) bacteriophage composition
CN110151727B (en) Composition for reducing acute toxicity caused by nanoparticles, preparation method and application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05817806

Country of ref document: EP

Kind code of ref document: A1